Read Gene

Read Gene Pre-Tax Margin

The Pre-Tax Profit Margin of Read Gene (RDG.WA) as of Oct 21, 2026 is 0.74 %. In the previous year, Pre-Tax Profit Margin was -4.36 % — a change of -116.95% (higher).

Pre-Tax Margin

0.74 %

YoY

-116.95%

Last updated:

Pre-Tax Profit Margin of Read Gene is 2025 0.74 % . Pre-Tax Profit Margin of Read Gene was 2024 -4.36 % . It decreases by -116.95% higher compared to the previous year.

The Read Gene Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
19.47 PLN
Jan 1, 2019
-1.86 PLN
Jan 1, 2020
6.04 PLN
Jan 1, 2021
0.81 PLN
Jan 1, 2022
0.84 PLN
Jan 1, 2023
-16.00 PLN
Jan 1, 2024
-4.36 PLN
Jan 1, 2025
0.74 PLN
The Read Gene Pre-Tax Margin history
YEARPre-Tax MarginYoY
0.74 %-116.95%
-4.36 %-72.78%
-16.00 %-2,006.81%
0.84 %+3.05%
0.81 %-86.52%
6.04 %-424.06%
-1.86 %-109.58%
19.47 %-1,277.67%
-1.65 %-67.42%
-5.07 %-84.53%
-32.80 %-70.29%
-110.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Pre-Tax Profit Margin of Read Gene is 0.74 % in 2025.

Pre-Tax Profit Margin of Read Gene changed from -4.36 % to 0.74 %, representing a -116.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Read Gene since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Read Gene

All Key Metrics — Read Gene